eye health

Aurinia eye drug falls short in improving tolerability versus Restasis, but beats on efficacy
Aurinia eye drug falls short in improving tolerability versus Restasis, but beats on efficacy
Endpoints
Aurinia Pharmaceuticals
voclosporin
eye health
dry eye disease
Allergan
Restasis
Flag link:
Novartis unit Alcon picks up Tear Film Innovations
Novartis unit Alcon picks up Tear Film Innovations
Mass Device
Novartis
Alcon
M&A
eye health
Tear Film Innovations
devices
Flag link:
Alcon's Acquisition Is a Real Tear-Jerker
Alcon's Acquisition Is a Real Tear-Jerker
Medical Devices and Diagnostics Industry
Alcon
Novartis
eye health
Flag link:
Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects
Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects
Fierce Pharma
Novartis
Alcon
spinoffs
SEC
eye health
Flag link:
New eye health companies gain funders’ focus
New eye health companies gain funders’ focus
Medical Design and Outsourcing
eye health
Flag link:
See, snap and fund: Johnson & Johnson Vision push for eye health to donate to charity for shared photos
See, snap and fund: Johnson & Johnson Vision push for eye health to donate to charity for shared photos
Fierce Pharma
JNJ
eye health
JNJ Vision
social media
Flag link:
Novartis says glaucoma stent setback will not derail Alcon spin-off
Novartis says glaucoma stent setback will not derail Alcon spin-off
Yahoo/Reuters
Novartis
glaucoma
Alcon
eye health
devices
CyPass Micro-Stent
Flag link:
FDA approves Kala's twice-daily ocular steriod
FDA approves Kala's twice-daily ocular steriod
BioCentury
Kala Pharmaceuticals
Inveltys
ocular steriods
eye health
Flag link:
Novartis to spin out Alcon ophthalmic subsidiary
Novartis to spin out Alcon ophthalmic subsidiary
Mass Device
Novartis
Alcon
opthalmology
eye health
devices
spinoffs
Flag link:
Report: Johnson & Johnson sees Vision Care biz grow, looks to expand beyond contacts
Report: Johnson & Johnson sees Vision Care biz grow, looks to expand beyond contacts
Mass Device
JNJ
eye health
Flag link:
Drug companies want Supreme Court to take eye drop dispute
Drug companies want Supreme Court to take eye drop dispute
Yahoo/AP
eye drops
eye health
Supreme Court
Allergan
Bausch & Lomb
Merck
Pfizer
Flag link:
Apellis touts new data for eye drug hopeful
Apellis touts new data for eye drug hopeful
Biopharma Dive
Apellis
eye health
APL-2
age-related macular degeneration
Flag link:
J&J Vision to acquire TearScience
J&J Vision to acquire TearScience
Mass Device
JNJ
TearScience
M&A
eye health
ophthalmology
Flag link:
Novartis unit Alcon posts modest Q2 gain
Novartis unit Alcon posts modest Q2 gain
Mass Device
Novartis
Alcon
eye health
earnings
devices
Flag link:
Potential Alcon sale worries Novartis investors
Potential Alcon sale worries Novartis investors
Drug Delivery Business News
Novartis
Alcon
devices
M&A
eye health
Flag link:
Horizon dives into eye treatments with River Visions acquisition
Horizon dives into eye treatments with River Visions acquisition
BioPharma Dive
Horizon Pharma
River Visions
M&A
eye health
Flag link:
Horizon Pharma buys River Vision and its fast-tracked eye med for $145M
Horizon Pharma buys River Vision and its fast-tracked eye med for $145M
Fierce Biotech
Horizon Pharma
River Vision
eye health
teprotumumab
thyroid eye disease
Flag link:
1Q17 Earnings for Novartis’s Alcon, Its Eye Care Business
1Q17 Earnings for Novartis’s Alcon, Its Eye Care Business
Market Realist
Novartis
earnings
Alcon
eye care
eye health
Flag link:
Novartis’s 1Q17 Estimates for Alcon
Novartis’s 1Q17 Estimates for Alcon
Market Realist
Novartis
Alcon
earnings
eye health
Flag link:
Ocular touts patient experience data for Dextenza implant
Ocular touts patient experience data for Dextenza implant
Drug Delivery Business News
devices
Ocular Therapeutix
eye health
Dextenza
post-surgical pain
Flag link:

Pages